Pharmaceutical

Novo Nordisk enters deal to develop obesity therapy

Novo Nordisk has entered into a deal with Flagship Pioneering and Metaphore Biotechnologies to develop therapeutics for obesity.

May 11, 2024 - 04:00
Novo Nordisk enters deal to develop obesity therapy
Novo Nordisk has entered into a deal with Flagship Pioneering and Metaphore Biotechnologies to develop therapeutics for obesity.
Read the original article

Tags:

Previous Article

Attovia secures $105m to advance development of lead programmes

Next Article

KITECH develops deformable energy storage device via laser technology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The Future for Biotesting

The Future for Biotesting

Apr 16, 2023

ESC 2024: Study highlights potential for Novartis to differentiate in HF space

ESC 2024: Study highlights potential for Novartis to di...

Sep 2, 2024

Merck is on the lookout for more opportunities within immunology

Merck is on the lookout for more opportunities within i...

Jan 29, 2024